TAKE Limited
TAKE Limited operates in Healthcare Research, Analytics & Technology, part of the Healthcare sector. It booked ₹30 cr of revenue in its latest quarter (Q1 FY27) and kept 3.5% of sales as profit. It is the 5th largest of 5 Healthcare Research, Analytics & Technology companies we track, by market value.
| Segment | FY21 | FY22 | Share |
|---|---|---|---|
| Life Sciences | 741 | 655 | 96% → 100% |
| Supply Chain Management | 33 | 0 | 4% → 0% |
| Total | 774 | 655 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 46% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 105–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 45
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in TAKE?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹30 cr |
| Other Income | ₹1 cr |
| Total Income | ₹32 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹30 cr |
| Employee Benefit Expense | ₹7.4 L |
| Finance Costs | ₹0.07 L |
| Depreciation & Amortisation | ₹0.02 L |
| Other Expenses | ₹29.6 L |
| Total Expenses | ₹31 cr |
| Profit before Tax | ₹1 cr |
| Tax Expense | ₹0 cr |
| Net Profit | ₹1 cr |
| Net margin on total income | 3.4% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 0 cr | 54 cr | 30 cr |
| Total income | 1 cr | 59 cr | 32 cr |
| Expenses | 35.2 L | 55 cr | 31 cr |
| Profit before tax | 1 cr | 4 cr | 1 cr |
| Tax | 0 cr | 0 cr | 0 cr |
| Net profit (owners' share) | 1 cr | 4 cr | 1 cr |
| Net margin (owners' share, on revenue) | — | 8.0% | 3.5% |
| EPS (₹) | 0.07 | 0.29 | 0.07 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Syngene International Limited | ₹380 | ₹15,349 cr | — | -0.7% | -1.2% | — |
| Indegene Limited | ₹592 | ₹14,232 cr | 30.6 | 14.8% | 10.9% | — |
| Suven Life Sciences Limited | ₹350 | ₹9,236 cr | — | -86.3% | — | — |
| Vimta Labs Limited | ₹600 | ₹1,332 cr | 19.1 | 25.1% | 23.9% | — |
| TAKE Limitedthis company | ₹17 | ₹248 cr | 60.0 | 13.7% | 3.5% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹0.4 / share | 1 Aug 2019 |
| Dividend | ₹0.3 / share | 22 Feb 2019 |
| Dividend | ₹0.3 / share | 9 Nov 2018 |
| Dividend | ₹0.4 / share | 2 Aug 2018 |
| Dividend | ₹0.6 / share | 2 Aug 2018 |
| Dividend | ₹0.3 / share | 15 Feb 2018 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.